Company intelligence / Profile preview

Cvergenx

Tampa, Florida, United States

Ownership: Private
Development stage: Other

Overview

Cvergenx has developed a genomics-based decision-support platform (pGRT) that uses the patented Radiosensitivity Index (RSI) and Genomic Adjusted Radiation Dose (GARD) to personalize radiotherapy dose; the platform is clinically validated retrospectively across multiple tumor types and is currently being prospectively evaluated in a Phase 2 trial in triple negative breast cancer (NCT05528133). [3][4]

Therapeutic areas: Oncology
Modalities: Non-pharmacological therapyDevice
Industry: Molecular Diagnostics

Partnerships

Moffitt Cancer Center[4]National Cancer Institute (Clinical Assay Development Program / CADP)[2]Predictive Oncology[3][6]

Beyond the preview

Go deeper on Cvergenx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cvergenx.

Explore the full profile